Brief: Eton Pharmaceuticals Expands Infantile Hemangioma Franchise
05/08/2026 13:06
BRIEF-Eton Pharmaceuticals Expands Infantile Hemangioma Franchise Aug 5 (Reuters) - Eton Pharmaceuticals Inc ETON.O:
ETON PHARMACEUTICALS EXPANDS INFANTILE HEMANGIOMA FRANCHISE WITH ACQUISITION OF U.S. RIGHTS TO LATE-STAGE PRODUCT CANDIDATE ASN-001
ETON PHARMACEUTICALS - ANTICIPATES NDA SUBMISSION FOR ASN-001 IN 2H 2027, POTENTIAL LAUNCH IN 2028
Source text: ID:nGNXTkZP6
Further company coverage: ETON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer